Company intelligence / Profile preview

Tunitas Therapeutics

San Francisco, California, United Statestunitastherapeutics.com ↗
Ownership
Private
Employees
~18
Development stage
Phase 1
01

Overview

Developed novel biologic therapies for serious allergies using engineered immune-modulating proteins; lead program discontinued after early-phase trials.

Therapeutic areas
PulmonologyDermatologyImmunology
Modalities
Fusion proteinsProtein therapeutics
Industry
Biotech
02

Drug pipeline

2 assets

GE2

Preclinical

1 more asset in the full pipeline.

03

Partnerships

Ally Bridge GroupWuXi VenturesRA Capital Advisors invested; no pharma partnerships disclosed yet.

Beyond the preview

Go deeper on Tunitas Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tunitas Therapeutics.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call